VC Fund Investments
Dermatology drug discoverer Ahammune Biosciences bags $5-M led by pi Ventures
Pune-based Ahammune Biosciences has raised USD 5 million in a Series A funding round led by early-stage venture fund, pi Ventures. The fundraise also saw participation from Capital2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, and existing investors, Ideaspring Capital, Kotak Alternate Assets, Legacy Assets LLP, and IAN.The company will use the fresh capital to conduct Phase II human clinical trials for its drug candidate for treating vitiligo (a chronic skin condition with a recurring appearance of white patches), expand its patent portfolio, and advance efforts for immune-mediated skin diseases.Founded in 2016 by Dr Parul Ganju and Dr Krishnamurthy Natarajan, Ahammune aims to become a drug discovery player in the dermatological sector.
In Apr 2021, Ahammune Biosciences had raised over USD 1.81 M from IAN Fund, Ideaspring, Kotak Investment Advisors, Munjal Family Office along with angel investors.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
